. Other studies, using alternative adjustments for confounders,
in the studies that presented such data has been that the risk of VTE appears to vary by duration and pattern of OC use.
The epidemiological studies that assessed the risk of venous
In the few studies that considered these patterns, however, thromboembolism (VTE) associated with newer oral condistinctions between first-time users and recurrent users were traceptives (OC) did not distinguish between patterns of either made broadly or not at all in the data analysis. This OC use, namely first-time users, repeaters and switchers.
distinction is important because we postulate that not only can Data from a Transnational case-control study were used duration of OC use be a principal source of bias in these to assess the risk of VTE for the latter patterns of use, studies, but these effects can also vary depending on whether while accounting for duration of use. Over the period the user is a new starter or has already used OC in the past.
1993-1996, 551 cases of VTE were identified in Germany
Indeed, we consider that the observed difference between the and the UK along with 2066 controls. Totals of 128 cases second and third generation OC risks of VTE may be largely and 650 controls were analysed for repeat use and 135 due to the fact that users of these two OC types vary by cases and 622 controls for switching patterns. The adjusted duration and pattern of use. It is expected that users of the rate ratio of VTE for repeat users of third generation OC newer pills in 1995 had a shorter duration of use than users was 0.6 (95% CI:0.3-1.2) relative to repeat users of second of older pills, a distinction that becomes crucial if the risk generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for varies by duration of OC use. To address this point, we switchers from second to third generation pills relative to previously used the Transnational Study data (Spitzer et al., switchers from third to second generation pills. We conclude 1996) to analyse the risk of VTE in first-time ever users of that second and third generation agents are associated with second and third generation pills as a function of the duration equivalent risks of VTE when the same agent is used of use (Suissa et al., 1997) . We found similar risk profiles for repeatedly after interruption periods or when users are both types of pills, namely that the risk, relative to non-users, switched between the two generations of pills. These anaincreases sharply to 10 in the first year of continuous use and lyses suggest that the higher risk observed for the newer decreases to around two thereafter for both types of pills. OC in other studies may be the result of inadequate Similar re-analyses were subsequently performed on the WHO comparisons of pill users with different patterns of pill use.
data (WHO, 1995a) with somewhat different findings (Farley Key words: deep venous thrombosis/epidemiological study / et al., 1998) , although several methodological reasons were pulmonary embolism/second and third generation oral contraoffered for these differences (Suissa and Spitzer, 1998) . It was impossible, with the data available in the Transnational study ceptives at the time, to estimate these risks in the subjects who were not first-time users. These data are now available and are the object of this article.
Introduction
In this paper, we use additional data on the history of OC use from the Transnational study (Spitzer et al., 1996) to Several recent epidemiological studies assessed the risk of assess the risks of VTE for second and third generation OC venous thromboembolism (VTE) associated with the use of in recurrent users who either used these products intermittently newer oral contraceptives (OC), that is low-dose oestrogen pills or switched between products. containing the newer progestagens desogestrel and gestodene. Some studies found that these so-called third generation OC Materials and methods had a higher risk of VTE relative to the second generation agent that contains levonorgestrel, with relative risks ranging
The data for this study come from the Transnational study (Spitzer et al., 1996) , which used a case-control design with subjects taken from 1.5 to 2.2 (Bloemenkamp et al., 1995; Jick et al., 1995;  from five European countries (Germany, UK, Austria, France and coded or prepared for data analysis until recently. Potential cona Some control subjects were used in both groups.
founding variables used were socio-demography, lifestyle, medical BMI ϭ body mass index.
history and family history of disease. The third generation OC were defined as those combining lowdose oestrogen (Ͻ35 µg ethinyl oestradiol) with either of the from odds ratios by logistic regression. Crude and adjusted odds desogestrel or gestodene progestagens. The second generation agents ratios were obtained for current use of any duration as well as by contained low-dose oestrogen with levonorgestrel or norgestimate; duration of OC use. The SAS statistical software package was used the latter was included in this group to remain consistent with previous for all analyses (SAS/STAT Software, 1996) . studies (WHO Collaborative Study, 1995a,b; Spitzer et al., 1996) . Current use of OC was defined as use in the 3 month period prior to Results the index date.
The present analysis involved only second and third generation
Of the 551 cases, we excluded 229 who used first generation agents, so that all subjects who used first generation high-dose years, although this effect is minimal and the CI were wide.
CI ϭ confidence interval.
The adjusted RR, given in Table VI , after switching from third to second generation pills compared to non-current use generation current users or non-current users. Switchers to third generation pills had shorter periods of current OC use, was 5.3 (95% CI 2.7-10.5), while after switching from second to third was 7.7 (95% CI 4.7-12.8). The direct comparison of prior use and of interruption than users of second generation pills. Thus, age, country, durations of prior OC use and of the the two pill classes resulted in an adjusted RR of 1.3 (95% CI 0.7-2.4) for switchers from second to third generation pills last interruption period were considered to be confounders and adjusted for in the estimation of the rate ratios (RR). Duration relative to switchers from third to second. To better understand this risk, we stratified our analyses by the number of prior of current use was controlled for by stratification.
Table IV provides the RR, estimated from odds ratios, for switches. For the majority of women who only switched once, the RR was 1.1 (95% CI 0.5-2.3), while among the few are made between subjects with similar durations and profiles of history of OC use. Besides the profile of first-time uninterrupmultiple switchers, the RR was 1.8 (95% CI 0.2-16.8). The RR did not vary according to the duration of the current ted use, which was considered in a prior paper, repeat but interrupted use of the same product and switching between episode of OC use (data not shown).
products must be considered separately. In addition, we also adjusted for durations of prior use and of interruption periods Discussion to make these profiles as similar as possible, and excluded subjects who had used first generation agents. This profile of An important finding of this study is that the risk of VTE is no different for repeat users of second and third generation use being an effect-modifier of the risk, it must be stratified for and analyses must be performed within strata. (Guess, OC, after adjustment for all confounding factors including the durations of the interruption period and of prior OC use. These 1989; Miettinen and Caro, 1989) . Thus, the overall results of all prior studies may be biased because they were based on subjects never switched products; they either always used a second or a third generation agent, albeit intermittently. Simuneven mixes of first-time users, repeaters and switchers, of second and third generation OC. ilarly, we found that women who switched from second to third generation agents had a similar risk of VTE as those Our study has limitations. First, unlike first-time users, repeaters and switchers are peculiar so that the findings who switched from third to second.
No other study has ever assessed the risks according to could be affected by several biases, including confounding by indication and selection bias. The repeaters have already been these profiles of OC use. The WHO study (WHO, 1995a ) was the only one in which the mix of recurrent users was investitested with one of these agents and have discontinued their use for a variety of usual reasons. However, the fact that they gated. It found that the risk of VTE among what were called 'former users' of OC was 1.8-fold higher for third than for restarted on the same agent indicates that the current users were able to tolerate well the agent they were on, with no second generation agents during the first year of use, and it was 2.3-fold higher thereafter (Poulter et al., 1996) . It is not need to change. On the other hand, the reference group of current non-users was made up of subjects who, like the clear how these former users were defined, although we can assume that they included both repeaters and switchers as well exposed subjects, stopped using OC but, unlike the exposed subjects, did not restart for reasons unknown to us. Indeed, if as users of first generation pills, while the reference group was ambiguous. Moreover, the analyses did not adjust for we had instead used as reference the 'never' users, the reference group we had used for first-time users (Suissa et al.,1997) , the durations of prior OC use and of interruption periods that we found to be relevant confounders. These two factors varied case to control odds would have been 47:271 instead of 54:443 for former users, which would reduce the RR by 30%. All the appreciably between the three comparison groups, which is expected because second and third generation pills appeared same, the RR for repeat use remain high, which does not concur with our findings for first-time users that indicated on the market at different times. And since the risk of VTE varies by duration of OC use, these factors turned out to be that the risk essentially disappeared after a few years of uninterrupted use both for second and third generation OC. relevant confounders. Unlike our findings for first-time users (Suissa et al., 1997) , however, the risk did not vary by duration
We surmise that these odds ratios relative to non-users may be biased for the unknown reasons that make repeaters start, of current OC use, and was particularly not higher in the first year of use. In our study, we observed that among repeaters interrupt and restart OC use. This could also be explained by selection bias, as subjects who were restarted on OC may have the rate of VTE was lower, although not significantly, for third than for second generation agents during the first year of use been more likely to be referred for a VTE examination and may have been more likely to have VTE diagnosed. as well as subsequently. On the other hand, the switchers from second to third generation agents had a slightly higher, although Nevertheless, although comparisons between the exposed and unexposed repeaters may be biased, the direct comparison not significant, rate of VTE than those who switched from third to second, for both the first year of use after the switch between repeaters of second and third generation agents are probably valid. For this latter comparison, we found that the as well as subsequently. Comparisons with the WHO study results are not possible because of its unclear definition of risks of VTE associated with second and third generation pills were not statistically different. Second, subjects who switched 'former users' and of the reference group, as well as the lack of adjustment for profile of use.
to another generation may have done so because of a lack of tolerance, and were channelled to a safer agent, or because of Our prior findings for first-time users (Suissa et al., 1997) show that the risks were identical for first-time users of second marketing effects. Channelling patients to safer agents, leading to confounding by indication, is common in non-experimental and third generation pills after duration of use is accounted for. Along with the present analyses, they suggest that all risk assessment of drugs (Petri and Urquhart, 1991) . Although VTE risk factors are not as well known as the arterial ones, a studies of the risks associated with OC use may have been biased because data analyses have been based simply on recent survey showed that women at higher risk of VTE were more likely to be switched from second to third generation current OC use, and have not considered the history of OC use. Indeed, when the history of use is taken into account, pills (Heinemann et al., 1996) . This may explain, at least in part, the RR of 1.3 among switchers, which was in any case both in terms of duration and profile, the risks of the two generations of pills are equivalent. Thus analyses of such not statistically significant. Thirdly, our sample size, although large overall, was not very large for certain analyses, with only epidemiological studies can only be valid if the comparisons
